Search for a clinical trial
Other search option(s)
15 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Terminated trial = 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
GERMANY
Baden-Württemberg
ULM
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Universitäts- und Rehabilitationskliniken Ulm (RKU)
Klinik für Neurologie
GERMANY
Bayern
MÜNCHEN
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
LMU Klinikum der Universität München - Campus Großhadern
Institut für Klinische Neuroimmunologie
GERMANY
Bayern
WÜRZBURG
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Neurologische Klinik und Poliklinik des Universitätsklinikums Würzburg
Neurologische Klinik und Poliklinik
GERMANY
Berlin
BERLIN
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Charité - Universitätsmedizin Berlin (CCM)
Klinik für Neurologie (CCM)
GERMANY
Niedersachsen
HANNOVER
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Medizinische Hochschule Hannover
Abteilung Klinische Neuroimmunologie und Neurochemie
GERMANY
Nordrhein-Westfalen
BOCHUM
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Neurologisches Universtätsklinikum im St. Josef-Hospital
Klinik für Neurologie
GERMANY
Nordrhein-Westfalen
MÜNSTER
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Universitätsklinikum Münster
Klinik für Neurologie mit Institut für Translationale Neurologie
GERMANY
Rheinland-Pfalz
MAINZ
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Universitätsmedizin Mainz
Klinik und Poliklinik für Neurologie
GERMANY
Schleswig-Holstein
KIEL
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Universitätsklinikum Schleswig-Holstein - Campus Kiel
Klinik für Neurologie
GERMANY
Thüringen
JENA
Generate-Boost: A Multicenter Randomized, Controlled, Double-blinded Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis (CONNECT-GENERATE study)
Universitätsklinikum Jena
Hans-Berger-Klinik für Neurologie
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
cosMOG: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD) - ES
Institution: Information not provided - ES
UNITED KINGDOM
Cambridgeshire
CAMBRIDGE
A Randomised Phase II Double-blinded Placebo-controlled Trial of Intravenous Immunoglobulins and Rituximab in Patients With Antibody-associated Psychosis (SINAPPS2)
University of Cambridge
Department of Medicine
UNITED KINGDOM
Greater London
LONDON
MS-STAT2: A phase 3 randomised, double blind, clinical trial investigating the effectiveness of repurposed simvastatin compared to placebo in secondary progressive multiple sclerosis, in slowing the progression of disability
University College London - UCL Darwin Building
University College London
UNITED KINGDOM
Oxfordshire
OXFORD